International Clinical Trial: A single-center, parallel-group, non-randomized controlled prospective study of efgartigimod administered at different cycles in patients with new-onset generalized myasthenia gravis (gMG)

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133923) titled 'A single-center, parallel-group, non-randomized controlled prospective study of efgartigimod administered at different cycles in patients with new-onset generalized myasthenia gravis (gMG)' on Oct. 9.

Study Type: Interventional study

Study Design: Non randomized control

Primary Sponsor: The First Hospital of China Medical University

Condition: Acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR-Ab? gMG)

Intervention: Group A:Efgartigimod IV, once a week, 4 times in a row, with 4-week intervals, on for 4 weeks and off for 4 weeks, for a total of 3 cycles Group B :Efgartigimod IV, on...